CA 19-9 as a Marker for Gastrointestinal Cancers: A Review

Duffy, Michael J.

doi:10.1177/000456329803500304

Cited by 108 publications

(75 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The A2M receptor, LRP, is overexpressed in human malignant astrocytomas, especially in GBM (22), and A2M can cross the blood-brain barrier in an LRP-dependent manner (23). CA 19-9 is known to be a circulating protein biomarker for gastrointestinal cancers (24). Although the expression and function of CA 19-9 in human glioma tissue are not well understood, increased CA 19-9 expression has been detected during tumorigenesis in a C6 rat glioma model, with this expression decreased after 8-Cl-cAMP treatment (25).…”

Section: Discussionmentioning

confidence: 99%

Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma

Gowda

et al. 2012

Int J Oncol

View full text Add to dashboard Cite

Abstract. Analyzing molecular biomarkers using blood is an important approach for clinical assessment of malignant glioma. We investigated a molecular proteomic biomarkerbased approach for glioblastoma using patients' blood samples. The expression levels of a list of candidate proteins were quantified in plasma and serum samples from two different cohorts of patients with malignant glioma and normal controls. The biological function was studied for one of the identified markers. Additionally, the prognostic significance of protein marker expression was measured by survival analysis. As a result, protein biomarkers associated with malignant glioma were identified from the blood specimens and five of the protein biomarkers were common to both cohorts. Immunohistochemical analysis demonstrated that many of the protein biomarkers identified in peripheral blood specimens were expressed in malignant gliomas. Staining levels for one of the biomarkers, MIP-1α, was found to correlate with WHO grade among invasive gliomas, and we demonstrate that MIP-1α promotes human glioblastoma cell proliferation and migration. Additionally, four prognostic protein biomarkers were identified. In conclusion, we demonstrate that both peripheral blood plasma and serum specimens are highly valuable and complementary to each other in the quest for protein biomarkers of malignant glioma. Sets of novel protein biomarkers were identified that may aid in the diagnosis and prognosis of patients with malignant glioma.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma

Gowda

et al. 2012

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…As a single diagnostic test, CA 19-9 increases in approximately 65 % of liver fluke-associated CCA [4] . Elevated concentrations of this marker have also been observed in patients with a variety of gastrointestinal cancers, as well as benign cholestasis and acute cholangitis [5] . As a result, a more sensitive and specific serum marker for the diagnosis of CCA is considered necessary.…”

Section: Introductionmentioning

confidence: 97%

Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma

Kongtawelert

Tangkijvanich²,

Ongchai³

et al. 2003

WJG

View full text Add to dashboard Cite

show abstract

“…The clinical decision of malignancy or benign was determined by final pathological diagnosis, which was based on results of operative biopsies, endoscopic biopsies, or surgical specimens. Patients among the original database with serum CA19-9 levels of <37u/ml, which was recommended in most literature as normal level 2,6,14,15 , were enrolled for further study. Patients lacking imaging support or pathological diagnosis as well as patients with metastasis were excluded.…”

Section: Methodsmentioning

confidence: 99%

“…Serum CA19-9 has a reported sensitivity of 70% to 90%, specificity of approximately 90%, positive predictive value of about 69%, and negative predictive value of about 90% in screening for pancreatic carcinoma 6 . However, elevated CA19-9 levels have also been found in several benign diseases, including chronic/acute pancreatitis, cholangitis, and lymphoepithelial cyst of the pancreas 2,7,8 .…”

Section: Introductionmentioning

confidence: 99%

Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels

Jin¹,

Wu²

2015

Afr H. Sci.

View full text Add to dashboard Cite

Background: Carbohydrate antigen (CA)19-9 that is the most widely used biomarker for pancreatic cancer has certain limitations in diagnosis, which results in a tough job to distinguish pancreatic cancer from benign tumors with normal CA19-9. The aim of this study was to investigate the diagnostic utility of clinical parameters and serum markers in patients with pancreatic head masses but without elevated CA19-9. Methods: Retrospectively, 106 (69 malignant, 37 benign) of 487 patients admitted for pancreatic head masses were enrolled with CA19-9 level of <37u/ml. Clinical parameters and serum biomarkers were assessed. Among the patients with pancreatic head mass, male individuals (p=0.025) and elder individuals (p<0.001) were more likely to have cancer; and cancer patients were more likely to present with abdominal-pain (p=0.023), weight-loss (p=0.013) and jaundice (p<0.001). Serum bilirubin levels among malignancies, including total bilirubin (p<0.001), direct bilirubin (p<0.001) and indirect bilirubin (p<0.001), were considerably higher than those of benign ones. Logistic regression further concluded that age-distribution, abdominal-pain and direct-bilirubin were three independent factors correlating with final diagnosis. However, CEA (p=0.156) was not sufficient enough to exclude pancreatic cancer. Conclusions: In patients with pancreatic head masses and CA19-9 of <37u/ml, age-distribution, abdominal-pain and direct bilirubin might be helpful in differential diagnosis. CEA was insufficient for exclusion of malignancy.

show abstract

CA 19-9 as a Marker for Gastrointestinal Cancers: A Review

Cited by 108 publications

References 36 publications

Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma

Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma

Role of serum total sialic acid in differentiating cholangiocarcinoma from hepatocellular carcinoma

Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels

Contact Info

Product

Resources

About